Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.85 -0.9%	$6.24	$3.93 ▼ $7.54	$350.17M	1.55	1.03 million shs	603,141 shs
ARCT Arcturus Therapeutics	$16.84 -6.0%	$13.68	$8.04 ▼ $25.88	$457.27M	2.26	471,287 shs	468,117 shs
CRVS Corvus Pharmaceuticals	$5.22 -2.0%	$4.29	$2.54 ▼ $10.00	$388.59M	0.42	807,225 shs	274,804 shs
ELUT Elutia	$2.02 -0.2%	$2.01	$1.61 ▼ $5.12	$82.60M	0.88	35,266 shs	15,520 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-3.09%	+10.03%	+4.86%	+7.63%	+38.20%
ARCT Arcturus Therapeutics	-8.06%	+57.24%	+32.67%	+41.02%	-11.34%
CRVS Corvus Pharmaceuticals	-2.03%	+21.74%	+24.88%	+44.57%	+29.76%
ELUT Elutia	0.00%	+2.54%	-4.72%	+10.99%	-44.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.4926 of 5 stars	3.5	2.0	4.5	3.1	2.5	1.3
ARCT Arcturus Therapeutics	2.885 of 5 stars	3.5	2.0	0.0	3.1	2.5	0.6
CRVS Corvus Pharmaceuticals	2.8999 of 5 stars	3.5	2.0	0.0	2.3	3.3	0.6
ELUT Elutia	3.6558 of 5 stars	3.5	5.0	0.0	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.50	184.88% Upside
ARCT Arcturus Therapeutics	3.00	Buy	$50.00	196.91% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	187.63% Upside
ELUT Elutia	3.00	Buy	$8.00	297.02% Upside

Current Analyst Ratings Breakdown

Latest ELUT, ARCT, CRVS, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $20.00
8/12/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $49.00
8/12/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $42.00
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$400K	875.42	N/A	N/A	$1.01 per share	6.78
ARCT Arcturus Therapeutics	$152.31M	3.00	N/A	N/A	$8.90 per share	1.89
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
ELUT Elutia	$23.68M	3.50	N/A	N/A	($1.31) per share	-1.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	$0.70	9.78	N/A	N/A	N/A	150.05%	59.86%	N/A
ARCT Arcturus Therapeutics	-$80.94M	-$2.23	N/A	N/A	N/A	-49.26%	-24.87%	-17.75%	11/6/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	N/A
ELUT Elutia	-$53.95M	-$1.06	N/A	N/A	N/A	-90.01%	N/A	-51.65%	N/A

Latest ELUT, ARCT, CRVS, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	$1.71	+$2.10	$1.71	$21.71 million	$0.40 million
8/14/2025	Q2 2025	ELUT Elutia	-$0.17	-$0.26	-$0.09	-$0.26	$6.55 million	$6.26 million
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	-$0.34	+$0.77	-$0.34	$17.64 million	$28.30 million
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
ARCT Arcturus Therapeutics	N/A	5.90	5.90
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
ELUT Elutia	N/A	0.81	0.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ARCT Arcturus Therapeutics	94.54%
CRVS Corvus Pharmaceuticals	46.64%
ELUT Elutia	74.03%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
ARCT Arcturus Therapeutics	15.30%
CRVS Corvus Pharmaceuticals	28.50%
ELUT Elutia	27.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	48.51 million	Optionable
ARCT Arcturus Therapeutics	180	27.16 million	23.00 million	Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	51.19 million	Optionable
ELUT Elutia	180	41.12 million	29.77 million	Not Optionable

ELUT, ARCT, CRVS, and ABEO Headlines

Recent News About These Companies

Analysts Have Been Trimming Their Elutia Inc. (NASDAQ:ELUT) Price Target After Its Latest Report

August 19 at 8:58 AM | finance.yahoo.com

Elutia price target lowered to $5 from $7 at Cantor Fitzgerald

August 18 at 3:09 PM | msn.com

Elutia (NASDAQ:ELUT) Releases Earnings Results

August 16 at 4:58 PM | marketbeat.com

Elutia Inc. (NASDAQ:ELUT) Q2 2025 Earnings Call Transcript

August 16 at 8:54 AM | insidermonkey.com

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

August 15, 2025 | taiwannews.com.twT

Elutia Inc. Reports Strong Growth and Strategic Advances

August 15, 2025 | msn.com

Elutia Posts Narrower Loss in Fiscal Q2

August 14, 2025 | aol.comA

Elutia targets $20M EluPro revenue run rate and NXT-41 launch in H2 2026 while advancing hospital penetration

August 14, 2025 | msn.com

Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript

August 14, 2025 | seekingalpha.com

Elutia Delivers Robust Growth on the Strength of EluProâ„¢ Market Adoption

August 14, 2025 | globenewswire.com

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award

August 1, 2025 | finance.yahoo.com

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

July 31, 2025 | globenewswire.com

Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award

July 31, 2025 | globenewswire.com

Elutia Inc. (NASDAQ:ELUT) Shares Bought by Perkins Capital Management Inc.

July 28, 2025 | marketbeat.com

AIGH Capital Management LLC Has $8.56 Million Stock Holdings in Elutia Inc. (NASDAQ:ELUT)

July 22, 2025 | marketbeat.com

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices

July 1, 2025 | manilatimes.netM

New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices

July 1, 2025 | globenewswire.com

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards - Morningstar

June 27, 2025 | morningstar.comM

5 Must-Read Analyst Questions From LeMaitre’s Q1 Earnings Call

June 27, 2025 | msn.com

Medical Device Network Excellence Awards 2025: Elutia

June 26, 2025 | medicaldevice-network.comM

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

June 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT, ARCT, CRVS, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.84 -0.07 (-0.94%)

As of 03:19 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Arcturus Therapeutics NASDAQ:ARCT

$16.84 -1.07 (-5.97%)

As of 03:20 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.22 -0.11 (-1.97%)

As of 03:19 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Elutia NASDAQ:ELUT

$2.02 -0.01 (-0.25%)

As of 03:18 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time